PrEP Nonadherence, White Coat Dosing, and HIV Risk Among a Cohort of MSM.

Cheríe S BlairMatthew R BeymerRyan M KofronRobert K BolanWilbert C JordanRichard H HaubrichAmy R WohlRaphael J Landovitz

Published in: Open forum infectious diseases (2020)

Among a cohort of men who have sex with men in a pre-exposure prophylaxis (PrEP) adherence trial, syphilis requiring treatment was associated with white coat dosing (increased PrEP adherence immediately preceding study visits) when compared with participants with optimal drug concentrations. The findings highlight the need for identifying and reducing barriers to PrEP adherence.

Keyphrases

men who have sex with men
hiv testing
hiv positive
clinical trial
antiretroviral therapy
human immunodeficiency virus
phase iii
hiv infected
metabolic syndrome
open label
skeletal muscle
hiv aids
south africa
smoking cessation
replacement therapy